Multiple_myeloma:_increased_circulating_lymphocytes_carrying_plasma_cell-associated_antigens_as_an_indicator_of_poor_survival._In_multiple_myeloma_(MM)_an_increase_in_circulating_lymphocytes_expressing_plasma_cell-associated_antigens_(PCAA)_has_been_described._Its_prognostic_significance_was_evaluated_in_this_study._The_immunologic_phenotype_of_peripheral_blood_lymphocytes_was_analyzed_with_a_panel_of_monoclonal_antibodies_specific_for_B,_T,_natural_killer_lymphocytes,_and_PCAA_(CD38,_PCA1)_in_52_MM_patients_at_diagnosis,_remission,_and_during_relapse,_18_monoclonal_gammopathy_of_undetermined_significance_(MGUS),_and_25_normal_controls._No_significant_phenotypic_alteration_was_observed_in_MGUS._In_MM,_the_number_of_B_lymphocytes_was_in_the_normal_range_at_diagnosis_and_during_the_subsequent_phases._A_CD4/CD8_ratio_decrease,_during_relapse,_was_due_to_both_a_CD4+_reduction_and_to_an_expansion_of_a_subset_of_CD8+_activated_suppressor_lymphocytes._CD38+_and_PCA1+_lymphocytes_at_diagnosis_were_significantly_higher_than_in_MGUS,_and_a_further_increase_was_observed_during_relapse,_suggesting_a_correlation_between_PCAA_expression_and_disease_activity._The_prognostic_significance_of_increased_PCAA_was_confirmed_by_a_survival_analysis_of_32_patients_evaluated_at_diagnosis_using_a_CD38_cutoff_of_0.45_x_10(9)/L_positive_lymphocytes._Median_survival_for_patients_with_high_values_was_only_14_months,_whereas_it_was_not_reached_at_32_months_by_those_with_low_values_(P_less_than_.0007).